LCAT and COVID-19: We found that patients with COVID-19 had significantly lower serum activities of LCAT and markedly impaired HDL functionality, such as reduced cholesterol efflux capacity, AE-activity of PON1, and AO-capacity, when compared to non-COVID pneumonia patients.